Evidence-Based Use of Colony-Stimulating Factors in Elderly Cancer Patients

Cancer Control

Volumn 10, Issue 6, 2003, Pages 487-499

  Lyman, Gary H ^a   Kuderer, Nicole ^a   Agboola, Olayemi ^a   Balducci, Lodovico ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; PACLITAXEL; PIRARUBICIN; PREDNIMUSTINE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENIPOSIDE; VINBLASTINE; VINCRISTINE;

CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DOSE RESPONSE; ECONOMIC ASPECT; FEBRILE NEUTROPENIA; GERIATRIC DISORDER; HOSPITALIZATION; HUMAN; INFECTION; NEUTROPENIA; PROPHYLAXIS; QUALITY OF LIFE; REVIEW;

EID: 0345168123     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480301000607     Document Type: Review

References (61)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Lyman GH. Essentials of clinical decision analysis: a new way to think about cancer and age. In: Balducci L, Lyman GH, Erschler W, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers; 1998:7-17.
3. Lyman GH, Kuderer N, Balducci L. Cancer care in the elderly: cost and quality of life considerations. Cancer Control. 1998;5:347-354.
4. Chatta GS, Dale DC. Aging and haemopoiesis: implications for treatment with haemopoietic growth factors. Drugs Aging. 1996;9:37-47.
5. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
6. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-411.
7. Marley SB, Lewis JL, Davidson RJ, et al. Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Br J Haematol. 1999;106:162-166.
8. Extermann M, Overcash J, Lyman GH, et al. Co-morbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
9. Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control. 2000;7:539-547.
10. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974-3979.
11. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27-34.
12. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival. A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
13. O'Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol. 1993;11:2250-2257.
14. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma. 1996;22:483-493.
15. Armitage JO, Potter JE Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984;32:269-273.
16. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840-3848.
17. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol. 1994;5(suppl 2):127-132.
18. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-242.
19. Lyman GH, Lyman C, Ogboola Y. Risk models for the prediction of chemotherapy-induced neutropenia. Neutropenia Oncol. 2001;1:2-7.
20. Lyman GH, Dale D, Crawford J. Incidence, practice patterns, and predictors of low dose intensity in adjuvant breast cancer chemotherapy: results of a nationwide survey of community oncology practices. J Clin Oncol. 2003;21. In press.
21. Paridaens R, Lyman GH, Leonard R, et al. Delivering optimal adjuvant chemotherapy in primary breast cancer: the role of rHuG-CSF. Eur J Cancer. 2003;1(suppl 9):1-12.
22. Rivera E, Erder MH, Moore TD, et al. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer. 2003;98:222-228.
23. Lyman GH. Risk assessment in oncology clinical practice: from risk factors to risk models. Oncology. 2003. In press.
24. Lyman GH, Morrison VA, Dale DC, et al, for the ANC Study Group. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069-2076.
25. Lyman GH, Delgado D. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin's lymphoma. Cancer. 2003. In press.
26. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk-index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
27. Lyman GH, Kuderer NM. Cost effectiveness of myeloid growth factors in cancer chemotherapy. Curr Hematol Rep. 2003;2:471-479.
28. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Supp Cancer Ther. 2003;1:1-13.
29. Lyman GH, Kuderer NM. Economics of hematopoietic growth factors. In: Morstyn G, Foote M, Lieschke GJ, eds. Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics. Totowa, NJ: Humana Press Inc; 2003:409-443.
30. Trillet-Lenoir V, Green JA, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-324.
31. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80:1430-1436.
32. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol. 1995;13:1564-1571.
33. Bui BN, Chevallier B, Chevreau C, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol. 1995;13:2629-2636.
34. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89:3974-3979.
35. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma. 1997;25:289-300.
36. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716-724.
37. Balducci L, Lyman GH. Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J Clin Oncol. 2001;19:1583-1585.
38. Lyman GH, Balducci L, Agboola Y. Use of hematopoietic growth factors in the older cancer patient. Oncol Spectrums. 2001;2:414-421.
39. Lyman GH, Kuderer NM, Balducci L. Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia. Curr Opin Oncol. 1998;10:291-296.
40. Lyman GH, Balducci L. Update of the economic analyses of the use of the colony-stimulating factors. Curr Opin Hematol. 1999;6:145-151.
41. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol. 2002;9:207-214.
42. Lyman GH, Lyman CG, Sanderson RA, et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85:488-493.
43. Lyman GH, Balducci L. A cost analysis of hematopoietic colony-stimulating factors. Oncology (Huntingt). 1995;9:85-91.
44. Lyman GH, Kuderer N, Greene J, et al. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998;34:1857-1864.
45. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001;6:441-445.
46. Cosler L, Calhoun E, Agboola O, et al. Impact of indirect and patient out-of-pocket costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for neutropenic complications from cancer chemotherapy. Pharmacotherapy. 2003. In press.
47. Fortner BV, Stolshek B, Schwartzberg LS, et al. Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel. Proc Annu Meet Am Soc Clin Oncol. 2002;21:2808. Abstract.
48. Okon TA, Fortner BV, Schwartzberg L, et al. Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Annu Meet Am Soc Clin Oncol. 2002;21:2920. Abstract.
49. Calhoun EA, Chang CH, Welshman EE, et al. A neutropenia-specific quality of life instrument: rationale for the development of the FACT-N. Proc Annu Meet Am Soc Clin Oncol. 2002;21:1498. Abstract.
50. Lyman GH, Kuderer NM. Incorporation of quality of life considerations into decision models for the use of colony stimulating factors in chemotherapy patients at risk for febrile neutropenia. In: Klastersky JA, ed. Febrile Neutropenia. Berlin; New York: Springer; 1997.
51. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62(suppl 1):65-78.
52. Talcott JA, Whalen A, Clark J, et al. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol. 1994;12:107-114.
53. Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71:3640-3646.
54. Sivasubramaniam V, Dale D, Crawford J, et al. Impact of outpatient treatment of febrile neutropenia (FN) on risk thresholds for G-CSF prophylaxis in cancer chemotherapy (CT). Proc Annu Meet Am Soc Clin Oncol. 2001;20:1563. Abstract.
55. Lyman GH. A New approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. Eur J Cancer. 2000;36(suppl):15-21.
56. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy. 2000;20:1045-1115.
57. Silber JH, Fridman, M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia dose reduction or delay in early-stage breast cancer therapy. J Clin Oncol. 1998;16:2392-2400.
58. Silber JH, Fridman M, Shpilsky A, et al. Modeling the cost-effectiveness of granulocyte-stimulating factor use in early-stage breast cancer. J Clin Oncol. 1998;16:2435-2444.
59. Lyman GH, Crawford J, Dale D, et al. Predicting the risk of chemotherapy-induced neutropenia (CIN) in patients with breast cancer: rationale for prospective risk model development. Breast Cancer Res Treat. 2002;76:S537.
60. Repetto L, Bigansoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force Guidelines for the use of the colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003:39:2264-2272.
61. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:3041-3050.